Providence Health Care has become the first centre in Canada to adopt the HeartFlow FFRct Analysis, and also first in the world to use the next generation version of the platform.
The HeartFlow FFRct Analysis, which was recently approved by Health Canada, is a non-invasive technology used by clinicians to assess their patients for coronary artery disease.
Developed by HeartFlow, the HeartFlow FFRct Analysis is the only non-invasive technology to provide insight into both the extent of coronary artery disease and the impact that disease has on blood flow to the heart, intended to aid clinicians in selecting an appropriate treatment. The latest generation of the HeartFlow FFRct Analysis is a cloud-based platform designed to allow for the more rapid processing of cases. According to a press release, the technology has been proven to reduce the need for invasive and costly procedures previously performed to diagnose patients suspected of having coronary artery disease.
Jonathon Leipsic, chairman of the Department of Radiology for Providence Health Care, says, “The technology offers us a deeper understanding of the extent of the coronary artery disease and risk it poses to the patient. This has very much changed our practice, allowing for more appropriate and personalised treatment decision making.”
The HeartFlow FFRct Analysis is a web-based platform that aids clinicians in diagnosing coronary artery disease, and provides personalised, actionable information to physicians to manage each patient. The technology provides mathematically computed fractional flow reserve (FFRct) values. The result is a personalised color-coded model of the patient’s coronary arteries that aids physicians in determining, vessel-by-vessel, if sufficient blood is reaching the heart.
